TreeFrog Therapeutics is a French biotechnology company specialized in cell therapy. Founded in 2018 by biophysicist Kévin Alessandri and stem cell biologist Maxime Feyeux in Bordeaux (France), TreeFrog Therapeutics develops a breakthrough technology – C-StemTM – which allows to mass-produce stem cell-derived cell therapies. Currently advancing cell therapy programs in Parkinson’s disease, liver failure and cancer, TreeFrog Therapeutics aims at making cell therapy safer, more efficient and widely available to large patient populations.
In October 2020, TreeFrog was awarded the prestigious Galien MedStartup Prize in New York. The company is listed in the FrenchTech120, which regroups the fastest-growing startups in France. Nowadays, Treefrog brings together over 100 stem cell biologists and bioproduction engineers. Over the past 4 years, the company raised over 82 million dollars.
In April 2022, Treefrog announced the opening of a lab in Kobe, Japan, with the aim of establishing strategic alliances with key academic and industrial players in the field of regenerative medicine.
Discover the company’s reception in Japan, their encountered challenges, and recommendations to other EU SMEs by reading our Case Study.
The EU-Japan Centre currently produces 5 newsletters :
Joint venture established in 1987 by the European Commission (DG GROW) and the Japanese Government (METI) for promoting all forms of industrial, trade and investment cooperation between the EU and Japan.
The EU-Japan Centre’s activities are subject to the allocation of a Grant Agreement by the European Commission for 2024-2026
